ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

(MedPage Today) — SAN ANTONIO — The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for metastatic hormone receptor-positive/HER2-negative breast cancer…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118963

Author :

Publish date : 2025-12-11 20:07:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

FDA Proposes Allowing New Sunscreen Ingredient

RFK Jr.’s Viral Pull-Ups; Docs Denounce ACIP’s Hep B Vote; ‘Don’t Pee!’

Related Posts

Vitamin C Isn’t a Cold Cure — Here’s What It Really Does

Mental health chat encouraged at coffee mornings

Lavender Tea Linked to Reduced Misophonia, Depression

GLP-1s Linked to Reduced Bleeding in Intracranial Aneurysms

Topical Calcineurin Inhibitors Show No Lymphoma Signal

More Pain at Discharge Tied to Higher Chances of Readmission

Vitamin C Isn’t a Cold Cure — Here’s What It Really Does

Mental health chat encouraged at coffee mornings

Lavender Tea Linked to Reduced Misophonia, Depression

GLP-1s Linked to Reduced Bleeding in Intracranial Aneurysms

Topical Calcineurin Inhibitors Show No Lymphoma Signal

More Pain at Discharge Tied to Higher Chances of Readmission

Families with children battling cancer to have travel costs covered

Older Folks Can Be Spared From Extended Surgery for Aortic Dissections

Categories

Archives